Scorpius Holdings awarded contract in excess of $1M with NIH-funded researcher

Scorpius Holdings announced that it has been awarded a contract in excess of $1M with an NIH-funded researcher at a major university. The program involves process optimization and development of a therapeutic antibody, which Scorpius will manufacture for preclinical studies. Jeff Wolf, CEO of Scorpius, stated, “Scorpius is excited to begin work with another nationally renowned university. Our selection by this leading researcher highlights our unique process development, bioanalysis, and manufacturing capabilities, which we have the ability to leverage into much larger projects as the programs progress through clinical stages and eventually into commercialization. There is a tremendous amount of innovative research being conducted at academic institutions, and Scorpius is well-suited to provide these clients with the attention and responsiveness they otherwise would not receive from a CDMO. Overall, we could not be more excited about the outlook for the business and the traction we are gaining.”